Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists

被引:42
作者
Saito, Tetsuji [1 ]
Obitsu, Tetsuo [1 ]
Minamoto, Chiaki [1 ]
Sugiura, Tsuneyuki [1 ]
Matsumura, Naoya [1 ]
Ueno, Sonoko [1 ]
Kishi, Akihiro [1 ]
Katsumata, Seishi [1 ]
Nakai, Hisao [1 ]
Toda, Masaaki [1 ]
机构
[1] Ono Pharmaceut Co Ltd, Minase Res Inst, Osaka 6188585, Japan
关键词
Corticotrophin-releasing factor 1 receptor; Antagonist; MAJOR DEPRESSION; HORMONE; DMP696; PHARMACOLOGY; POTENT;
D O I
10.1016/j.bmc.2011.08.055
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To identify structurally novel CRF1 receptor antagonists, a series of bicyclic core antagonists, pyrazolo [1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines, imidazo[1,2-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines were designed, synthesized and evaluated as CRF1 receptor antagonists. Compounds 2-27 showed binding affinity (IC50 = 4.2-418 nM) and antagonist activity (EC50 = 4.0-889 nM). Compound 5 was found to show oral efficacy in an Elevated Plus Maze test in rats. Further chemical modification of them led us to discovery of the tricyclic core antagonists pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidines. The discovery process of these compounds is presented, as is the study of the structure-activity relationship. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5955 / 5966
页数:12
相关论文
共 18 条
[1]   Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists [J].
Arban, Roberto ;
Benedetti, Roberto ;
Bonanomi, Giorgio ;
Capelli, Anna-Maria ;
Castiglioni, Emiliano ;
Contini, Stefania ;
Degiorgis, Fabio ;
Di Felice, Pina ;
Donati, Daniele ;
Fazzolari, Elettra ;
Gentile, Gabriella ;
Marchionni, Chiara ;
Marchioro, Carla ;
Messina, Flavia ;
Micheli, Fabrizio ;
Oliosi, Beatrice ;
Pavone, Francesca ;
Pasquarello, Alessandra ;
Perini, Benedetta ;
Rinaldi, Marilisa ;
Sabbatini, Fabio M. ;
Vitulli, Giovanni ;
Zarantonello, Paola ;
Di Fabio, Romano ;
St-Denis, Yves .
CHEMMEDCHEM, 2007, 2 (04) :528-540
[2]  
BANKI CM, 1987, AM J PSYCHIAT, V144, P873
[3]   CHARACTERIZATION OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR-MEDIATED ADENYLATE-CYCLASE ACTIVITY IN THE RAT CENTRAL NERVOUS-SYSTEM [J].
BATTAGLIA, G ;
WEBSTER, EL ;
DESOUZA, EB .
SYNAPSE, 1987, 1 (06) :572-581
[4]   Corticotrophin-releasing factor receptors: From molecular biology to drug design [J].
Chalmers, DT ;
Lovenberg, TW ;
Grigoriadis, DE ;
Behan, DP ;
DeSouza, EB .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (04) :166-172
[5]   Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics [J].
Chen, C .
CURRENT MEDICINAL CHEMISTRY, 2006, 13 (11) :1261-1282
[6]  
DEBELLIS MD, 1993, AM J PSYCHIAT, V150, P656
[7]   Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists [J].
Han, XJ ;
Michne, JA ;
Pin, SS ;
Burris, KD ;
Balanda, LA ;
Fung, LK ;
Fiedler, T ;
Browman, KE ;
Taber, MT ;
Zhang, J ;
Dubowchik, GM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (17) :3870-3873
[8]   Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: Correlation with drug exposure and anxiolytic efficacy [J].
Li, YW ;
Hill, G ;
Wong, H ;
Kelly, N ;
Ward, K ;
Pierdomenico, M ;
Ren, S ;
Gilligan, P ;
Grossman, S ;
Trainor, G ;
Taub, R ;
McElroy, J ;
Zazcek, R .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (01) :86-96
[9]  
Li YW, 2005, CNS DRUG REV, V11, P21
[10]   The CRF1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats [J].
McElroy, JF ;
Ward, KA ;
Zeller, KL ;
Jones, KW ;
Gilligan, PJ ;
He, LQ ;
Lelas, S .
PSYCHOPHARMACOLOGY, 2002, 165 (01) :86-92